论文部分内容阅读
钙流拮抗剂(CEB)是七十年代发展起来的一类新型心血管药物,近年来动物实验及临床研究表明,CEB对支气管哮喘有预防及治疗作用,有可能成为一类新型的治疗支气管哮喘药物,引起人们极大的兴趣。
Calcium flow antagonist (CEB) is a new type of cardiovascular medicine developed in the seventies. In recent years, animal experiments and clinical studies have shown that CEB can prevent and treat bronchial asthma and may become a new type of treatment for bronchial asthma Drugs, aroused great interest.